Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its target price reduced by analysts at Bank of America from $14.00 to $12.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s price objective indicates a potential upside of 128.57% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. Morgan Stanley decreased their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Finally, Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.30.

Y-mAbs Therapeutics Stock Up 8.2 %

Shares of NASDAQ YMAB opened at $5.25 on Wednesday. The firm’s fifty day moving average is $6.39 and its 200 day moving average is $10.58. Y-mAbs Therapeutics has a 52 week low of $4.25 and a 52 week high of $18.17. The company has a market cap of $235.14 million, a price-to-earnings ratio of -9.72 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the firm earned ($0.02) EPS. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Large investors have recently made changes to their positions in the business. Paradigm Biocapital Advisors LP grew its stake in shares of Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after buying an additional 150,000 shares during the last quarter. Acorn Capital Advisors LLC purchased a new position in Y-mAbs Therapeutics during the fourth quarter valued at $22,408,000. Caligan Partners LP boosted its holdings in Y-mAbs Therapeutics by 47.9% in the fourth quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock worth $13,843,000 after acquiring an additional 572,729 shares in the last quarter. State Street Corp increased its holdings in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Y-mAbs Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock valued at $6,440,000 after acquiring an additional 8,820 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.